{"url_path":"/sec/pmi/10-q/2026/item-1a","section_key":"item-1a","section_title":"Item 1A RISK FACTORS**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/2030617/0001437749-26-017342-index.html","accession_number":"0001437749-26-017342","cik":"0002030617","ticker":"PMI","issuer_name":"Picard Medical, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2030617/0001437749-26-017342-index.html","primary_entity_key":"0002030617","primary_entity_name":"Picard Medical, Inc."},"word_count":386,"has_tables":true,"body_markdown":"**ITEM 1A. RISK FACTORS**\n\n \n\nFactors that could cause our actual results to differ materially from those in this Quarterly Report are any of the risks described in *Part I, Item 1A. Risk Factors*of our Form 10-K, filed with the SEC on March 30, 2026. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. Except for as set forth below, as of the date of this Quarterly Report, there have been no material changes to the risk factors disclosed in *Part I, Item 1A. Risk Factors*of our Form 10-K, filed with the SEC on March 30, 2026, except we may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.\n\n \n\n**There can be no assurance that we will be able to comply with the continued listing standards of the NYSE.**\n\n \n\nOn May 8, 2026, we received the NYSE Notice from the NYSE indicating we were no longer in compliance with the Section 1003(a)(ii) in the Company Guide since the Company reported stockholders’ equity of $3.8 million as of December 31, 2025, and had net losses in three of its four most recent fiscal years then ended (the \"Stockholders' Equity Rule\"). The Company intends to submit its Plan by June 7, 2026, advising of actions it has taken or will take to regain compliance with Section 1003(a)(ii) of the Guide by November 8, 2027. There can be no guarantee that NYSE will accept the Company’s Plan or that the Company will regain compliance by the November 8, 2027, deadline.\n\n \n\nIf the NYSE delists our Class A common stock from trading on its exchange and we are not able to list such securities on another national securities exchange, we expect such securities could be quoted on an over-the-counter market. If this were to occur, we and our stockholders could face significant material adverse consequences including:\n\n \n\n \n\n●\n\nA limited availability of market quotations for our common stock;\n\n \n\n \n\n●\n\nReduced liquidity for our common stock;\n\n \n\n \n\n●\n\nA limited amount of news and analyst coverage; and\n\n \n\n \n\n●\n\nA decreased ability to obtain additional financing in the future."}